INTRODUCTION

Myelofibrosis (MF) is a clonal malignancy of hematopoietic cells characterised by progressive bone marrow fibrosis, splenomegaly, inefficient haematopoiesis, constitutional symptoms and bone pain. MF can either develop de novo (primary MF) or secondary to polycythaemia vera (PV) or essential thrombocythaemia (ET). Survival in patients with myeloproliferative neoplasms (MPNs) is shorter compared with the general population and particularly pronounced for MF. MF can either develop de novo (primary MF) or secondary to polycythaemia vera (PV) or essential thrombocythaemia (ET). Survival in patients with myeloproliferative neoplasms (MPNs) is shorter compared with the general population and particularly pronounced for MF. Furthermore, MF is often...
associated with a profound negative effect on quality of life.\textsuperscript{3} Approximately 8%-20% of patients with MF eventually transform into acute myeloid leukaemia and consequently have an even shorter survival.\textsuperscript{4-6}

Historically, available treatment options for MF have been symptomatic with limited or no disease modifying potential. In a Swedish population-based study, Hultkrantz et al\textsuperscript{2} described improved survival outcomes in MPN patients over the last decades; however, the improvement was less pronounced after the calendar year 2000 and confined to patients with PV and ET, suggesting dismal outcomes with current treatment options for MF in clinical practice. Recent evidence suggests that the Janus kinase (JAK) signalling pathway may play a central role in the pathogenesis of MF. Results from clinical studies suggest that the JAK-1/2 inhibitor ruxolitinib is effective in reducing symptoms of MF, which also has translated into improved quality of life.\textsuperscript{1} Ruxolitinib was approved based on the results of two phase-III studies that compared ruxolitinib with placebo or best available care. The US Food and Drug Administration approved ruxolitinib for intermediate and high-risk MF,\textsuperscript{7,8} while the European Medicines Agency approved ruxolitinib for treatment of splenomegaly and/or constitutional symptoms of MF, irrespective of risk group.\textsuperscript{1} There is limited evidence to show that ruxolitinib improves survival outcomes by modifying the disease course, although its effect on metabolic and nutritional variables may translate into survival benefits.\textsuperscript{9} Eventually, most patients discontinue treatment due to adverse events or lack of efficacy.\textsuperscript{9} In recent phase-III studies, about 50% of patients discontinued ruxolitinib within 3 years of treatment.\textsuperscript{7} Salvage therapy options remain scarce\textsuperscript{10} and mostly include allogeneic stem cell transplantation (allo-SCT) followed by immunomodulators; however, prognosis is unfavourable.\textsuperscript{9} Although allo-SCT is the only curative treatment, it is rarely used in Sweden and Norway in this patient population due to the significant risk of morbidity and mortality.\textsuperscript{11}

Randomised controlled clinical trials are critical tools when assessing benefits of novel agents compared to standard of care. However, longitudinal observational studies can be an invaluable complement to these studies in the evaluation of patient outcomes in clinical practice. The present study is the first national population-based study to describe survival outcomes in MF patients receiving ruxolitinib outside clinical trial settings in Sweden and Norway.

2 | PATIENTS AND METHODS

2.1 | Data sources and patient selection

All residents of Sweden (\textapprox{}10 million) and Norway (\textapprox{}5 million) receive health care through one universal national system, and a unique personal identification number is assigned to each resident at birth which enables linkage between registers. All malignant disorders have been registered in the nationwide Swedish Cancer Register since 1958, and since 1984, there has been a double reporting routine where clinicians and pathologists/cytologists are obliged by law to report all new cases of cancer. Similarly, in Norway, registration of new malignant cases has been compulsory since 1951.

For the present study, inclusion criteria were age \geq{}18 years at MF diagnosis (identified by ICD7: 209 [Sweden]; ICD-O/3: 9975/3, 9960/3, 9961/3 [Norway]) in the national cancer registries (Sweden: 2001-2015; Norway: 2002-2016) and at least one record of ruxolitinib (ATC: L01XE18) in the Prescribed Drug Registries (2013-2017) (Figure 1). The total observation time for the Prescribed Drug Registry in Sweden was from June 2005 to September 2017. The completeness and diagnostic accuracy of the national Cancer Registers have been demonstrated to be about 96% in Sweden\textsuperscript{12} and 98% in Norway.\textsuperscript{13} Although the Cancer Register has a high overall coverage, there has been a certain degree of under-reporting of indolent malignancies such as MPNs and Waldenström Macroglobulinemia.\textsuperscript{14,15} Mortality data were collected from the Cause of Death Registries (Sweden: January, 2014 to November, 2017; Norway: January, 2014 to September 2017).

The study was approved by the Regional Ethical Review Board in Stockholm and the SOR-OST Regional Ethics Committee in Norway. The study was also approved by the National Board of Health and Welfare in Sweden, and the National Agency of Data Protection in Norway, for patient integrity and data handling. Informed consent was waived since there was no contact with study objectives.

2.2 | Study design and data collection

This was a retrospective cohort study. All patients who received ruxolitinib (n = 190) were followed from treatment initiation until death, censoring or end of follow-up ([Sweden] November 2017; [Norway] October, 2017). Patients who discontinued ruxolitinib treatment were followed from ruxolitinib discontinuation until death, censoring.

![FIGURE 1] Patient selection [Colour figure can be viewed at wileyonlinelibrary.com]
or end of follow-up. Ruxolitinib treatment duration was defined as the time between the date of the first dispensation to the date of the last dispensation plus the number of days of assumed drug supply for the last dispensation (28 days for one package (56 tablets) and 56 days if ≥2 packages were dispensed) in the Prescribed Drug Register.

2.3 | Statistical analysis

Overall survival (OS) and relative survival (RS) were estimated. For the RS analyses, excess mortality of MF patients compared with a general population matched on age, gender, calendar year at diagnosis and country, was calculated. Excess mortality rate ratios (EMRRs) were also estimated to assess the effect of age, sex and time from MF diagnosis to start of ruxolitinib on excess mortality. Mortality data of the general population used for RS and EMRR estimates were obtained from the Human Mortality Database.\textsuperscript{16} In addition, we investigated the loss in life expectancy (LEL) from ruxolitinib initiation and discontinuation using flexible parametric models adjusted for age, sex, calendar year and country.\textsuperscript{17} LEL was calculated as the difference in life expectancy of MF patients from their index dates and that of the matched population. For the Swedish cohort, the number of patients receiving other MF-specific treatments as defined in the Nordic MPN recommendations\textsuperscript{18} before, during and after ruxolitinib were summarised descriptively. Drugs dispensed before or on the date of the first ruxolitinib dispensation were considered treatment before ruxolitinib, and drugs dispensed after or on the date of the last ruxolitinib dispensation were considered treatment after ruxolitinib. Drugs dispensed between the first and the last ruxolitinib dispensation dates were considered dispensed during ruxolitinib treatment. RS and EMRRs were estimated using the relsurv package in R. LEL analyses were conducted using stpm2 package in STATA.

3 | RESULTS

Among the 190 patients who received ruxolitinib, 101 were Swedish and 89 were Norwegian. Twenty-four patients died during the observation period, and 95 remained on treatment at the end of follow-up. Most patients had primary MF, median age at MF diagnosis was 64 years (inter quartile range [IQR]: 55,71) and 53.2% were male. Median time from MF diagnosis to ruxolitinib treatment initiation was 3.2 years (IQR 1.1,5.9) and median ruxolitinib treatment duration was 11.5 months (IQR 5.2,22.0) (Table 1).

Median follow-up time from ruxolitinib initiation and discontinuation, respectively, were 16.6 (IQR: 8.5,32.2) and 5.4 (IQR: 1.6,16.9) months. For all survival analyses we only report RS since OS was

**TABLE 1** Baseline characteristics of myelofibrosis patients receiving ruxolitinib

|                      | Sweden (n = 101) | Norway (n = 89) | Merged (n = 190) |
|----------------------|-----------------|----------------|-----------------|
| Number of patients with primary myelofibrosis (n, %) | 100 (99%) | 89 (100%) | 189 (99.5%) |
| Age (years) at diagnosis, median (IQR) | 63 (54, 71) | 65 (56, 70) | 64 (55, 71) |
| Sex, male (n, %) | 50 (49.5) | 51 (56.0) | 101 (53.2) |
| Median time (years) from diagnosis to start of ruxolitinib treatment (IQR) | 3.2 (1.1, 6.2) | 3.3 (1.0, 4.9) | 3.2 (1.1, 5.9) |
| Median ruxolitinib treatment duration (months) (IQR) | 11.9 (6.0, 21.0) | 10.8 (4.8, 24.7) | 11.5 (5.2, 22.0) |

Abbreviation: IQR, interquartile range.

**FIGURE 2** A, Relative survival from ruxolitinib treatment initiation (n = 190), B, Relative survival from ruxolitinib treatment discontinuation (n = 71)
identical to RS. From ruxolitinib initiation, 1- and 4-year RS were 0.80 (95% confidence interval [CI]: 0.74, 0.86) and 0.52 (95% CI: 0.42, 0.64), respectively (Figure 2A). EMRR was greater in patients aged >70 vs <60 years (3.16; 95% CI: 1.34-7.40). Sex and time from MF diagnosis to ruxolitinib treatment initiation were not associated with risk of death (Table 2). Among patients who discontinued ruxolitinib (n = 71), median RS from treatment discontinuation was 16.0 months (95% CI: 6.3, NE) (Figure 2B). From ruxolitinib treatment, discontinuation none of the studied variables in the EMRR model were significantly associated with excess mortality (Table 2). The average MF-related LEL from ruxolitinib initiation was 11 years, and the corresponding LEL from ruxolitinib discontinuation was 12 years.

For the Swedish patients (n = 101), hydroxyurea (n = 73) was the most commonly used treatment before ruxolitinib initiation, followed by glucocorticoids (n = 53) and peginterferon alfa-2a (n = 17). During ruxolitinib treatment, glucocorticoids (n = 27) was frequently added and some patients also received hydroxyurea (n = 12). After ruxolitinib discontinuation (n = 37), a proportion of patients received glucocorticoids (n = 24), hydroxyurea (n = 12) and busulfan (n = 3) (Table 3).

### TABLE 2 Excess mortality rate ratios (EMRRs) in myelofibrosis patients from ruxolitinib treatment initiation (n = 190) and discontinuation (n = 71)

| Covariate                        | EMRR (95% CI) From ruxolitinib initiation | P value | EMRR (95% CI) From ruxolitinib discontinuation | P value |
|----------------------------------|------------------------------------------|---------|-----------------------------------------------|---------|
| Sex                              |                                          |         |                                               |         |
| Female                           | 1.00 (reference)                         |         | 1.00 (reference)                              |         |
| Male                             | 1.54 (0.86, 2.76)                        | 0.15    | 1.93 (0.93, 4.02)                             | 0.08    |
| Age at diagnosis                 |                                          |         |                                               |         |
| <60                              | 1.00 (reference)                         |         | 1.00 (reference)                              |         |
| 60-70                            | 1.13 (0.43, 2.97)                        | 0.8     | 1.10 (0.33, 3.65)                             | 0.88    |
| >70                              | 3.16 (1.34, 7.40)                        | 0.008   | 1.83 (0.59, 5.66)                             | 0.29    |
| Time from diagnosis to ruxolitinib initiation |                      |         |                                               |         |
| <1 y                             | 1.00 (reference)                         |         | 1.00 (reference)                              |         |
| >1 y                             | 0.71 (0.37, 1.36)                        | 0.304   | 0.66 (0.30, 1.43)                             | 0.29    |

### TABLE 3 Treatments used by Swedish myelofibrosis patients receiving ruxolitinib

| Treatment | Before ruxolitinib (n = 101) | During ruxolitinib (n = 101) | After ruxolitinib (n = 37) |
|-----------|------------------------------|------------------------------|-----------------------------|
| Busulfan  | 2                            | 0                            | 3                           |
| Hydroxyurea | 73                          | 12                           | 12                          |
| Anagrelide | 10                           | 2                            | 0                           |
| Danazol   | 3                            | 1                            | 2                           |
| Interferon alfa-2b | 1                  | 0                            | 0                           |
| Peginterferon alfa-2a | 17               | 4                            | 2                           |
| Peginterferon alfa-2b | 4                  | 0                            | 0                           |
| Thalidomide | 8                            | 0                            | 2                           |
| Azathioprine | 4                            | 1                            | 0                           |
| Methotrexate | 2                            | 0                            | 0                           |
| Lenalidomide | 0                           | 1                            | 0                           |
| Glucocorticoids | 53                   | 27                           | 24                          |

### DISCUSSION

In the present study, Swedish and Norwegian registries were used to estimate survival in MF patients treated with ruxolitinib in clinical practice. The study demonstrates poor RS compared with a matched general population and emphasizes the lack of effective salvage treatment options after ruxolitinib discontinuation.

Follow-up studies of the COMFORT-I and COMFORT-II trials showed that half of the patients discontinued ruxolitinib within 3 years and another 25% discontinued within 5 years from ruxolitinib initiation. In controlled clinical trial settings, the most frequently reported causes of treatment discontinuation were disease progression, adverse events and lack of efficacy. These findings were also supported by Kuykendall et al in a retrospective, single-centre study in the US and by Palandri et al in a retrospective database analysis including data from 23 European hematology centres. Data on reasons for ruxolitinib discontinuation were not available in the present study. In a clinical phase I/II study, Newberry et al reported a median survival of 14 months from ruxolitinib
discontinuation and concluded that low platelet counts at initiation or discontinuation of ruxolitinib therapy as well as clonal evolution during therapy may predict a worse prognosis. However, generalizability of these findings may be limited due to a single-centre design.

Although not presented in the current study, crude OS estimates were identical to the RS estimates, which is in line with what one would expect given age distribution and short expected survival in the late stage disease of interest in the present study. Since there is a scarcity of similar studies reported in available literature, the possibility to compare our results with those of other studies is limited. In the US study, Kuykendall et al reported a median OS from ruxolitinib discontinuation of 13 months in MF patients with low to high Dynamic International Prognostic Scoring System (DIPSS) scores. In the present study, median RS was 16 months after ruxolitinib discontinuation. However, these results should be interpreted with caution since few patients (n = 20) were alive at 16 months, resulting in a wide confidence interval (95% CI: 6.3–NE). Also, these results may not be comparable with the US study since the latter included healthier patients (low to high DIPSS scores). In the present study, although no information on DIPSS or International Prognostic Scoring System scores were available, it was assumed that most of the patients had intermediate-2 or high-risk MF, since ruxolitinib treatment is only reimbursed and recommended for patients within these risk groups in Sweden and Norway. Furthermore, in another retrospective study in the US, Mehta et al reported a median OS of 14 months in patients who discontinued ruxolitinib. However, Palandri et al reported a median OS of 22.6 months (95% CI, 13.2-30.7), which is superior compared with what we report in the present study (16 months, 95% CI, 6.3-NE). Distribution of patient characteristics and differences in reasons for treatment discontinuation may be reasons for this rather small difference.

Previous studies have reported that allo-SCT, lenalidomide, thalidomide, interferon, danazol and hydroxyurea are frequently used after ruxolitinib discontinuation. In the present study, the most commonly used drugs were glucocorticoids (65.9%) followed by hydroxyurea (32.4%). The lack of effective treatment options is likely to contribute to high mortality rates.

The main strength of this study was the quality of data, that is complete national coverage from two countries, population-based and longitudinal. Study limitations included small sample sizes, no information on risk scores and relatively short follow-up since ruxolitinib has only been available in clinical practice since 2013 in Sweden and Norway. In addition, we did not have access to information on allo-SCT if patients received treatments within clinical trials. Furthermore, since we only included patients with MF who received ruxolitinib treatment, findings may not be generalizable to a broader MF population. Since patients that received a MF diagnosis early in the observation period per definition had to survive long enough to get access to ruxolitinib, we included time from MF diagnosis to ruxolitinib initiation as a covariate in the EMRR model. However, since index date is set to ruxolitinib initiation and discontinuation, and not MF diagnosis, the risk for immortal time bias is minimised. This assumption was also confirmed by the EMRR analyses since there was no statistical association with death when comparing patients with MF diagnosis less or more than 1 year from ruxolitinib initiation. Results from the present study may be generalizable to corresponding patient populations in countries that have a healthcare system and treatment guidelines comparable to that in Sweden and Norway.

This is the first real-world study using nationwide population-based data to describe survival outcomes in MF patients who received ruxolitinib. The study results corroborate previous findings in similar patient populations and show that patients who discontinued ruxolitinib treatment had poor survival outcomes. Treatment options after ruxolitinib discontinuation were scarce and mostly limited to palliative care, highlighting the need for more effective therapeutic options.

ACKNOWLEDGEMENTS
The authors thank Prabhakar Pandey (Siro Clinpharm Pvt Ltd) for providing medical writing support and Harry Ma, PhD (Janssen Research & Development, LLC) for additional editorial assistance.

CONFLICT OF INTEREST
CS, EV, JL, CL and JH are employees of Janssen. JL and CL hold stocks in the company. FS was an employee of Janssen at the time this study was conducted, and currently, she is an employee and owner of Schain Research AB and work as a consultant for Janssen. MB has previously received consultancy fees from Janssen.

AUTHOR CONTRIBUTIONS
FS, JL, JH and MB contributed to the conception and design; FS and JL acquired the data; EV, CS, JL, CL, FS, JH and MB contributed to data analysis and interpretation. All authors were involved in drafting the manuscript and approval of the final manuscript for submission.

ORCID
Frida Schain https://orcid.org/0000-0002-7671-9471

REFERENCES
1. Cervantes F, Pereira A. Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood. 2017;129(7):832–837.
2. Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30(24):2995-3001.
3. Mesa RA, Schwager S, Radia D, et al. The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199-1203.
4. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905-914.
5. Martí-Carvajal AJ, Anand V, Solá I. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis. Cochrane Database of Syst Rev. 2015;(4)
6. Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29(17):2410-2415.

7. Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139-1145.

8. Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156.

9. Kuykendall AT, Shah S, Talati C, et al. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018;97(3):435-441.

10. Al‐Ali HK, Griesshammer M, le Coutre P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016;101(9):1065-1073.

11. Deeg HJ, Bredeson C, Farnia S, et al. Hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: long-term success in all age groups. Biol Blood Marrow Transplant. 2015;21(11):1883-1887.

12. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish cancer register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27-33.

13. Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218-1231.

14. Lundblom AR, Bower H, Andersson TM, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018;32(10):2203-2210.

15. Turesson I, Linet MS, Bjorkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007;121(10):2260-2266.

16. Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). 2018; www.mortality.org. Accessed 7 March, 2018.

17. Andersson TM, Dickman PW, Eloranta S, Lambe M, Lambert PC. Estimating the loss in expectation of life due to cancer using flexible parametric survival models. Stat Med. 2013;32(30):5286-5300.

18. Nordic MPN study group. Nordic care program for patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis. http://www.mpn.org/. 2017.

19. Palandri F, Elli EM, Polverelli N, et al. Outcome of patients with myelofibrosis after ruxolitinib failure: role of disease status and treatment strategies in 214 patients paper presented at: American society of hematology annual meeting 2018; San Diego, CA, USA.

20. Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017;130(9):1125-1131.

21. Mehr M, Potluri R, He J, Wang G, Mundle S, Bussolari J. Characterization of disease, treatment patterns, and outcomes of patients with myelofibrosis: analysis of two united states commercial claims databases. American Society of Hematology (ASH) 58th Annual Meeting; December 3-6, 2016, 2016; San Diego, CA, USA.

How to cite this article: Schain F, Vago E, Song C, et al. Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway. Eur J Haematol. 2019;103:614–619. https://doi.org/10.1111/ejh.13330